It is used for qualitative detection of IgM-class antibodies to Epstein-barr virus capsid antigen in human serum or plasma. It is intended to be used in clinical laboratories for diagnosis and management of patients related to infection with Epstein-barr virus. EBV infection is widespread, with more than 90% of the world's population having been infected with the virus, and EBV is characterized as an insidious infection, with primary infections occurring in infants and adolescents, mainly as asymptomatic, and adolescents presenting with infectious mononucleosis. After primary infection, EBV is usually latent in human mature B lymphocytes. Under certain conditions, the latent virus can be activated, stimulating cell proliferation and differentiation, and in some cases, eventually transforming into malignant diseases such as lymphoma, with a poor prognosis, so early detection of EBV should not be ignored. EBV is one of the causes of several malignancies (e.g. nasopharyngeal carcinoma) and it mainly infects epithelial cells and B lymphocytes in the human oropharynx. EBV tests have antibody and antigen tests. EBV antibody tests include antibodies related to viral capsid antigen (VCA), early antigen (EA), viral nuclear antigen (EBNA), and membrane antigen (MA), and are commonly used clinically to detect EB-VCA-IgM and EB-VCA-IgG. The EB-VCA-IgM test detects antibodies in the acute phase of the patient, and a positive result for this item is Early, specific and sensitive basis for clinical diagnosis.
